Semaglutide and Fatty Liver Disease: What the MASH Research Shows

Fatty liver disease affects roughly one in three adults in the United States, yet most people have no idea they have it until a routine blood test or imaging scan turns up something unexpected. For years, the only treatment was lifestyle change: lose weight, improve your diet, exercise more. Good advice, but for many people, very hard to sustain.

Now there is a growing body of clinical evidence suggesting that semaglutide, the active compound in Ozempic and Wegovy, may directly benefit people with fatty liver disease. The research has moved quickly, from early-stage trials showing promise to a major Phase 3 study published in the New England Journal of Medicine in 2025. This article walks through what the science actually shows.

*This article is for educational and informational purposes only. It does not constitute medical advice. Compounded semaglutide is not FDA-approved for fatty liver disease or MASH. Consult your licensed healthcare provider before making any changes to your treatment plan.*

---

What Is NAFLD and MASH?

Fatty liver disease goes by a few names, and the terminology has recently been updated by medical organizations to reflect a better understanding of the condition.

NAFLD (non-alcoholic fatty liver disease) is the older umbrella term for excess fat accumulation in the liver in people who drink little or no alcohol. Within that category, the more serious form was called NASH (non-alcoholic steatohepatitis), where inflammation and liver cell damage accompany the fat buildup.

In 2023, the major liver disease societies agreed on updated terminology:

• NAFLD is now called MASLD (metabolic dysfunction-associated steatotic liver disease)
• NASH is now called MASH (metabolic dysfunction-associated steatohepatitis)

The name change reflects something important: this is fundamentally a metabolic condition, closely tied to obesity, insulin resistance, and type 2 diabetes. You will see both sets of names in the medical literature depending on when a study was published.

Why MASH matters: When fatty liver progresses to MASH, the combination of fat, inflammation, and cellular injury can lead to fibrosis (scarring of liver tissue). Over time, fibrosis can advance to cirrhosis and liver failure. MASH is now one of the leading causes of liver transplants in the United States.

---

The Connection Between Obesity and Fatty Liver

Excess body fat, especially fat stored around the abdomen and organs, is the primary driver of fatty liver disease in most people. Here is the basic chain of events:

Insulin resistance comes first. When cells become less responsive to insulin, the body compensates by producing more of it. High insulin levels signal fat cells to release more fatty acids into the bloodstream, and the liver absorbs and stores them.

The liver gets overwhelmed. When more fat arrives than the liver can process and export, it accumulates as droplets within liver cells. At this stage, the condition is relatively mild.

Inflammation develops. In some people, the excess fat triggers oxidative stress and inflammatory signals. This is the transition from simple steatosis (fat accumulation) to steatohepatitis (fat plus inflammation), the more dangerous MASH stage.

Fibrosis follows. Chronic inflammation activates specialized liver cells called stellate cells, which lay down scar tissue. Once fibrosis takes hold, the clock starts on a potentially serious progression.

This is why obesity treatment and fatty liver treatment are so deeply connected. Losing a meaningful amount of body weight, roughly 7 to 10 percent of starting weight, can substantially reduce liver fat and even reverse early-stage fibrosis.

*Metabolic markers including BMI, waist circumference, fasting insulin, and liver enzymes are all interconnected in fatty liver disease.*

---

What the Research Shows

The GLP-1 Class: Early Evidence from the LEAN Trial

The first rigorous clinical trial demonstrating that a GLP-1 receptor agonist could improve fatty liver disease was published in The Lancet in 2016. Known as the LEAN trial, the study tested liraglutide (a once-daily GLP-1 agonist) versus placebo in 52 patients with biopsy-confirmed NASH.[^1]

After 48 weeks, 39 percent of patients receiving liraglutide had resolution of NASH on liver biopsy, compared to 9 percent of those receiving placebo. Rates of fibrosis progression were also lower in the liraglutide group.

The trial was small and used liraglutide rather than semaglutide. But it established proof of concept that the GLP-1 class could improve liver disease beyond simply helping people lose weight. It set the stage for semaglutide-specific research.

Phase 2 Semaglutide Data

In 2021, the first Phase 2 trial specifically testing semaglutide in NASH was published in the New England Journal of Medicine.[^2] Researchers randomized 320 patients with biopsy-confirmed NASH to receive once-daily subcutaneous semaglutide at three dose levels (0.1, 0.2, or 0.4 mg) or placebo for 72 weeks.

At the highest dose (0.4 mg), 59 percent of patients achieved NASH resolution, compared to 17 percent in the placebo group. Average weight loss in the highest-dose group was approximately 13 percent of body weight.

There was a notable finding on fibrosis: while NASH resolved at much higher rates with semaglutide, the improvement in liver fibrosis scores did not reach statistical significance. This left a key question open: could semaglutide actually reduce scarring in the liver, or was it mainly reducing inflammation?

That question led directly to the ESSENCE trial.

The ESSENCE Trial: Phase 3 Evidence

The ESSENCE trial is the most significant study to date on semaglutide and fatty liver disease. Published in the New England Journal of Medicine in 2025, the trial enrolled 1,197 patients with biopsy-confirmed MASH and moderate-to-advanced fibrosis (stage 2 or 3).[^3]

Patients were assigned in a 2:1 ratio to receive weekly semaglutide 2.4 mg (the same dose used for weight loss in Wegovy) or placebo. The results reported here are from a planned interim analysis at 72 weeks.

Primary endpoint 1 (fibrosis improvement without worsening of MASH): achieved in 36.8 percent of the semaglutide group versus 22.4 percent of the placebo group.

Primary endpoint 2 (MASH resolution plus fibrosis improvement): achieved in 32.7 percent of the semaglutide group versus 16.1 percent of the placebo group.

Both endpoints were statistically significant, and both exceeded the pre-specified targets. Patients receiving semaglutide also lost a mean of 10.5 percent of body weight during the 72-week period, compared to 2.0 percent in the placebo group.

These results answer the question the Phase 2 trial could not: semaglutide at the weight-loss dose does appear to reduce liver fibrosis in people with MASH, not just resolve inflammation.

The ESSENCE trial is ongoing, with the full 240-week results still to come.

---

How GLP-1 Receptor Agonists Affect the Liver

The benefits seen in these trials likely involve multiple mechanisms working together.

Weight loss itself reduces liver fat significantly. A 10 percent reduction in body weight is associated with substantial decreases in liver fat content and improvement in MASH-related inflammation. Much of the liver benefit from semaglutide may simply reflect the profound weight loss the medication produces.

Direct hepatic effects are also plausible. GLP-1 receptors are expressed in the liver, though their density is lower than in pancreatic tissue. Preclinical research suggests semaglutide may reduce inflammation in liver cells through GLP-1 receptor-mediated pathways, independent of weight loss. Whether this direct effect is clinically meaningful in humans is still being studied.

Insulin sensitivity improves. By reducing insulin resistance, semaglutide lowers the flux of fatty acids into the liver, reducing the raw material for fat accumulation. Improved insulin sensitivity also reduces the inflammatory signals that drive the transition from simple steatosis to MASH.

Appetite reduction lowers caloric intake. Semaglutide acts on appetite centers in the brain, significantly reducing hunger and food intake. This contributes to caloric restriction, which further reduces hepatic fat deposition.

The honest answer from the current science is that all of these mechanisms probably contribute, and their relative importance may vary from person to person.

---

What This Means If You Have Obesity and Fatty Liver

The research here has real practical implications.

If you have been diagnosed with fatty liver disease (whether called NAFLD, MASLD, NASH, or MASH) and you are also carrying excess weight, the connection between the two is not coincidental. They share the same metabolic root causes. Treating one often helps the other.

The ESSENCE trial did not enroll patients based on weight loss desire; it enrolled patients with significant liver disease and measured liver outcomes. The fact that semaglutide produced meaningful improvements in both MASH resolution and fibrosis reduction, alongside substantial weight loss, speaks to how tightly connected metabolic health and liver health are.

People with fatty liver disease should have a frank conversation with their clinician or hepatologist about their full metabolic picture, including their candidacy for GLP-1 therapy if weight is a contributing factor.

---

Is Semaglutide FDA-Approved for Fatty Liver Disease?

Not yet, and this distinction matters.

As of April 2026, semaglutide is FDA-approved for:

• Type 2 diabetes management (as Ozempic, 2017)
• Chronic weight management in adults with obesity or overweight with a weight-related condition (as Wegovy, 2021)
• Cardiovascular risk reduction in adults with obesity and established cardiovascular disease (as Wegovy, 2024)

It is not FDA-approved specifically for MASH, NAFLD, or liver disease. Resmetirom (brand name Rezdiffra), approved by the FDA in March 2024, holds the distinction of being the first drug specifically approved for MASH with fibrosis.

Novo Nordisk has stated it is pursuing regulatory approval of semaglutide for MASH based on the ESSENCE trial data. That process is ongoing.

What this means for compounded semaglutide specifically: Compounded semaglutide is not FDA-approved for any indication, including weight management. It is prescribed by licensed healthcare providers through the compounding pharmacy model. If you have a clinician managing both your weight and a liver condition, any discussion of semaglutide for liver-related reasons involves off-label use, which your provider would need to evaluate and guide.

---

The Broader Cardiovascular Picture

It is worth noting that people with MASH carry elevated cardiovascular risk. The metabolic syndrome, insulin resistance, and abdominal obesity that drive fatty liver disease are also major contributors to heart disease.

The SELECT trial, published in 2023, demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 percent in people with obesity and established cardiovascular disease who did not have diabetes.[^4] A 20 percent relative risk reduction in MACE is a clinically meaningful result.

For someone managing both fatty liver disease and elevated cardiovascular risk, the data suggest semaglutide may address multiple problems through a shared metabolic mechanism.

---

How Prescriva Fits In

Prescriva connects you with licensed healthcare providers who can evaluate your full metabolic picture, including weight, lab values, and health history, to determine whether a GLP-1 treatment program is appropriate for you.

If your lab work shows elevated liver enzymes, or if you have been told you have fatty liver, share that with your provider. This context is directly relevant to your treatment plan.

Prescriva does not treat liver disease, and compounded semaglutide is not prescribed by providers in Prescriva's affiliated network for that purpose. Your provider will evaluate whether you are a candidate for weight management support, and if so, will help you set goals appropriate to your full health picture.

[Learn more about how Prescriva works](/how-it-works)

---

The Bottom Line

Semaglutide has moved from an intriguing possibility to a well-documented intervention for fatty liver disease. The LEAN trial established that GLP-1 agonists could resolve NASH. The Phase 2 semaglutide trial confirmed robust MASH resolution rates. The ESSENCE trial showed, in a large Phase 3 study, that semaglutide 2.4 mg significantly improves both liver inflammation and fibrosis in people with MASH.

The weight loss mechanism almost certainly contributes a major share of the liver benefit. But the consistent signal across multiple trials, in multiple patient populations, points to something real. For people carrying both excess weight and a diagnosis of fatty liver disease, this research is worth knowing.

As always, the conversation about whether semaglutide is right for you belongs with your healthcare provider.

---

*This article is for educational and informational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication or treatment. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.*

---

References

[^1]: Armstrong MJ, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet*. 2016;387(10019):679-690. [PMID: 26608256](https://pubmed.ncbi.nlm.nih.gov/26608256/)

[^2]: Newsome PN, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. *N Engl J Med*. 2021;384(12):1113-1124. [PMID: 33185364](https://pubmed.ncbi.nlm.nih.gov/33185364/)

[^3]: Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. *N Engl J Med*. 2025;392(21):2089-2099. [PMID: 40305708](https://pubmed.ncbi.nlm.nih.gov/40305708/)

[^4]: Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389(24):2221-2232. [PMID: 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)